Vandeweyer Geert, Helsmoortel Céline, Van Dijck Anke, Vulto-van Silfhout Anneke T, Coe Bradley P, Bernier Raphael, Gerdts Jennifer, Rooms Liesbeth, van den Ende Jenneke, Bakshi Madhura, Wilson Meredith, Nordgren Ann, Hendon Laura G, Abdulrahman Omar A, Romano Corrado, de Vries Bert B A, Kleefstra Tjitske, Eichler Evan E, Van der Aa Nathalie, Kooy R Frank
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26. doi: 10.1002/ajmg.c.31413. Epub 2014 Aug 28.
Mutations in ADNP were recently identified as a frequent cause of syndromic autism, characterized by deficits in social communication and interaction and restricted, repetitive behavioral patterns. Based on its functional domains, ADNP is a presumed transcription factor. The gene interacts closely with the SWI/SNF complex by direct and experimentally verified binding of its C-terminus to three of its core components. A detailed and systematic clinical assessment of the symptoms observed in our patients allows a detailed comparison with the symptoms observed in other SWI/SNF disorders. While the mutational mechanism of the first 10 patients identified suggested a gain of function mechanism, an 11th patient reported here is predicted haploinsufficient. The latter observation may raise hope for therapy, as addition of NAP, a neuroprotective octapeptide named after the first three amino acids of the sequence NAPVSPIQ, has been reported by others to ameliorate some of the cognitive abnormalities observed in a knockout mouse model. It is concluded that detailed clinical and molecular studies on larger cohorts of patients are necessary to establish a better insight in the genotype phenotype correlation and in the mutational mechanism.
ADNP 突变最近被确定为综合征性自闭症的常见病因,其特征为社交沟通和互动缺陷以及局限的重复行为模式。基于其功能结构域,ADNP 被认为是一种转录因子。该基因通过其 C 末端与 SWI/SNF 复合体的三个核心成分直接结合并经实验验证,从而与该复合体密切相互作用。对我们患者所观察到的症状进行详细而系统的临床评估,有助于与其他 SWI/SNF 疾病所观察到的症状进行详细比较。虽然最初确定的 10 例患者的突变机制提示功能获得机制,但此处报告的第 11 例患者预计为单倍体不足。后一观察结果可能为治疗带来希望,因为其他人曾报告称,添加 NAP(一种以序列 NAPVSPIQ 的前三个氨基酸命名的神经保护八肽)可改善基因敲除小鼠模型中观察到的一些认知异常。得出的结论是,有必要对更多患者群体进行详细的临床和分子研究,以便更好地了解基因型-表型相关性和突变机制。